Ronald W. Penczek

Chief Financial Officer

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 1 saleApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (6 ops.)

€1.5M

Latest filing published 15 Jun 2026 for Elevance Health, Inc.. Read the official filing

Filing timeline

BuySale

Ronald W. Penczek

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Ronald W. Penczek: trading record in brief

Ronald W. Penczek, listed as finance chief, appears in our data through filings on Elevance Health, Inc. shares, published by SEC (Form 4). Between 28 October 2021 and 12 June 2026, the trades on record add up to 12 filings.

The open-market record consists of 6 sales worth €1.5M, with no purchase. No amount is published for 1 filing, which the totals therefore leave out. Besides market trades, the filings include 5 share grants and 1 option exercise. In 2026 alone, the filings show no purchases and 1 sale.

The newest entry dates from 15 June 2026: an open-market sale, in Elevance Health, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.